^
Association details:
| Biomarker: | RBM10 underexpression + EGFR mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer
Excerpt:
We stratified EGFR mutant patients by median RBM10 mRNA expression and found that patients whose tumors expressed lower levels of RBM10 progressed earlier on EGFR TKI therapy (PFS: RBM10 low = 11.6 months, RBM10 high = 16.7 months, Wilcoxon test p-value = 0.03)...Decreased PFS in the RBM10 low cohort was associated with decreased initial tumor response rates...
DOI:
10.1101/2020.10.26.356352
